Education
About Us
Working with TipRanks
Follow Us
MoonLake Immunotherapeutics (MLTX)
NASDAQ:MLTX
RESEARCH TOOLSreports
Total Valuation
MoonLake Immunotherapeutics has a market cap or net worth of $2.70B. The enterprise value is $2.98B.
Market Cap$2.70B
Enterprise Value$2.98B
Share Statistics
MoonLake Immunotherapeutics has 63,474,255 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding63,474,255
Owned by Insiders27.07%
Owned by Institutions0.28%
Financial Efficiency
MoonLake Immunotherapeutics’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-0.27
Return on Assets (ROA)-0.25
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee-1.21B
Employee Count100
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of MoonLake Immunotherapeutics is -0.03. MoonLake Immunotherapeutics’s PEG ratio is >-0.01.
PE Ratio-0.03
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF-0.03
Price to Operating Cash Flow-0.03
PEG Ratio>-0.01
Income Statement
In the last 12 months, MoonLake Immunotherapeutics had revenue of 0.00 and earned -120.68B in profits. Earnings per share was -1.92K.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income-120.96B
Net Income-120.68B
EBITDA0.00
Earnings Per Share (EPS)-1.92K
Cash Flow
In the last 12 months, operating cash flow was -116.59B and capital expenditures -519.52K, giving a free cash flow of -117.11B billion.
Operating Cash Flow-116.59B
Free Cash Flow-117.11B
Free Cash Flow per Share-1.84K
Dividends & Yields
MoonLake Immunotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.27
52-Week Price Change-1.15%
50-Day Moving Average38.95
200-Day Moving Average46.24
Relative Strength Index (RSI)63.05
Average Volume (3m)511.39K
Important Dates
MoonLake Immunotherapeutics upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 26, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
MoonLake Immunotherapeutics as a current ratio of 21.11, with Debt / Equity ratio of <0.01%
Current Ratio21.11
Quick Ratio21.11
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, MoonLake Immunotherapeutics has paid -282.20M in taxes.
Income Tax-282.20M
Effective Tax Rate<0.01
Enterprise Valuation
MoonLake Immunotherapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -0.03.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-0.03
EV to Operating Cash Flow-0.03
Balance Sheet
MoonLake Immunotherapeutics has $448.03B in cash and marketable securities with $282.58K in debt, giving a net cash position of -$448.02B billion.
Cash & Marketable Securities$448.03B
Total Debt$282.58K
Net Cash-$448.02B
Net Cash Per Share-$7.06K
Tangible Book Value Per Share$7.21K
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for MoonLake Immunotherapeutics is $77.40, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$77.40
Price Target Upside83.94% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast―
EPS Growth Forecast-147.80%